EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 / No 6-7 (Juin-Juillet 2023) Med Sci (Paris), 39 6-7 (2023) 575-577 References
Open Access
Issue
Med Sci (Paris)
Volume 39, Number 6-7, Juin-Juillet 2023
Page(s) 575 - 577
Section Forum
DOI https://doi.org/10.1051/medsci/2023076
Published online 30 June 2023
  1. Goldman M, Dewatripont M, Fischer A. L’innovation thérapeutique au service du bien commun. Med Sci (Paris) 2022; 38 : 859–60. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Jordan B. Une thérapie très attendue… et un prix exorbitant ! Med Sci (Paris) 2023; 39 : 187–90. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Jordan B. Bénéfice clinique et coût des traitements anticancéreux. Med Sci (Paris) 2020; 36 : 1095–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020. JAMA Intern Med 2022 ; 182 : 1319–1320. [CrossRef] [PubMed] [Google Scholar]
  5. Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005–2022. J Cancer Policy 2022; 34 : 100364. [CrossRef] [PubMed] [Google Scholar]
  6. van Harten WH, Wind A, de Paoli P, Saghatchian M, Oberst S. Actual costs of cancer drugs in 15 European countries. Lancet Oncol 2016 ; 17 : 18–20. [CrossRef] [PubMed] [Google Scholar]
  7. Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 2020; 21 : 664–70. [CrossRef] [PubMed] [Google Scholar]
  8. Egilman AC, Rome BN, Kesselheim AS. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare. JAMA 2023; 329 : 1283–9. [CrossRef] [PubMed] [Google Scholar]
  9. Jordan B. Une approche pragmatique pour gérer les traitements onéreux. Med Sci (Paris) 2017 ; 33 : 1121–1123. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.